Andrew Aromando insider trades: Oncolytics Biotech (ONCY) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Andrew reports to the SEC
Open-market buys and sales
1 trade reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Feb 11, 2026 | ONCY | ↑ Buy | 29,600 | $0.86 | $25K | Direct | Feb 13, 2026 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other ONCY insiders
Open-market trades in the last 12 months
About Andrew Aromando's insider trades
Andrew Aromando is Chief Business Officer at Oncolytics Biotech (ONCY). Since Feb 11, 2026, Andrew has reported 1 open-market purchase worth $25K and no sales on SEC Form 4. In the last 12 months: 1 buy ($25K).
Their filings also include grants and awards (4 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ONCY insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.